₹448.5
▲ +5.14 +1.16%
10 Sept 2026
NSE Listed · Pharmaceuticals
Cohance Lifesciences Ltd. (COHANCE)
Volume: 8,07,343Avg Vol 1W: 10,94,909Avg Vol 1M: 11,66,32352W Range:₹266.7₹1,027
Key Ratios
Checked just nowMarket Cap₹17,159 Cr
Current Price₹448.5
Previous Close₹443.36
High / Low (52w)₹1,027 / ₹266.7
Volume8,07,343
Avg Vol (1W)10,94,909
Avg Vol (1M)11,66,323
Stock P/E159.61
Book Value₹102.23
Dividend Yield0%
ROE5.05%
ROA102.15%
Revenue (TTM)—
Revenue Growth13.91%
Profit Margin496.05%
Total Debt₹6 Cr
Shares Outstanding38 Cr
Face Value₹1
EPS (TTM)₹2.81
P/B4.39
Debt / Equity0.12
50 DMA₹444.47
200 DMA₹422.02
Day change+1.16%
Price Chart
₹448.5▼ 54.69% · 1Y
2025-09-102026-09-10
20-day avg volume: 12.3L shares
Pros
- Company is almost debt-free.
Cons
- Revenue fell 37% YoY.
- Stock trades at a high P/E of 160.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹604 Cr | ₹676 Cr | ₹840 Cr | ₹549 Cr | ₹556 Cr | ₹545 Cr | ₹619 Cr | ₹422 Cr |
| EBITDA | ₹184 Cr | ₹215 Cr | ₹187 Cr | ₹81 Cr | ₹93 Cr | ₹55 Cr | ₹46 Cr | ₹-36 Cr |
| Net Profit | ₹138 Cr | ₹153 Cr | ₹120 Cr | ₹49 Cr | ₹74 Cr | ₹37 Cr | ₹20 Cr | ₹-24 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,678 Cr | ₹769 Cr | ₹484 Cr | ₹498 Cr | ₹482 Cr | ₹568 Cr | ₹2,303 Cr | ₹360 Cr |
| EBITDA | ₹699 Cr | ₹188 Cr | ₹86 Cr | ₹126 Cr | ₹76 Cr | ₹78 Cr | ₹274 Cr | ₹4 Cr |
| Net Profit | ₹487 Cr | ₹123 Cr | ₹53 Cr | ₹94 Cr | ₹47 Cr | ₹35 Cr | ₹179 Cr | ₹1 Cr |
| EPS | 12.68 | — | — | — | — | — | 4.68 | — |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹783 Cr | ₹1,173 Cr | ₹1,474 Cr | ₹1,830 Cr | ₹1,966 Cr | ₹2,254 Cr | ₹5,481 Cr | ₹5,730 Cr |
| Total Liabilities | ₹193 Cr | ₹328 Cr | ₹294 Cr | ₹302 Cr | ₹231 Cr | ₹203 Cr | ₹1,688 Cr | ₹1,696 Cr |
| Equity | ₹590 Cr | ₹845 Cr | ₹1,181 Cr | ₹1,527 Cr | ₹1,735 Cr | ₹2,051 Cr | ₹3,793 Cr | ₹4,034 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹83 Cr | ₹493 Cr | ₹492 Cr | ₹514 Cr | ₹603 Cr | ₹468 Cr | ₹849 Cr | ₹436 Cr |
| Investing | ₹-65 Cr | ₹-413 Cr | ₹-311 Cr | ₹-136 Cr | ₹-195 Cr | ₹-362 Cr | ₹-390 Cr | ₹-255 Cr |
| Financing | ₹26 Cr | ₹7 Cr | ₹-76 Cr | ₹-156 Cr | ₹-242 Cr | ₹-14 Cr | ₹-327 Cr | ₹-165 Cr |
| Free Cash Flow | ₹83 Cr | ₹493 Cr | ₹492 Cr | ₹514 Cr | ₹603 Cr | ₹468 Cr | ₹849 Cr | ₹436 Cr |
Shareholding
Promoter 57.49% Institutions 26.59% Public 15.93%
Efficiency & Working Capital
ROCE5.5%
Interest Coverage6.6
Dividend Payout—
Debtor Days110 d
Inventory Days90 d
Payable Days46 d
Cash Conversion Cycle154 d
Working Capital Days200 d
Shareholding Details
As of 2026-06-30
Promoter57.5%
FII6.5%
DII20.1%
Institutions26.6%
Public15.9%
Promoter Pledge94.6%
No. of Shareholders99,149
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | May 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.1% | 50.1% | 50.1% | 50.1% | 50.1% | 66.4% | 66.4% | 66.4% | 57.5% | 57.5% | 57.5% | 57.5% |
| FIIs | 9.5% | 9.8% | 10.7% | 10.8% | 11% | 7.4% | 7.4% | 7.2% | 6.5% | 6% | 5.6% | 6.5% |
| DIIs | 17.2% | 17.4% | 16.9% | 16.7% | 16.6% | 11% | 11% | 11.4% | 20.8% | 21.6% | 21.8% | 20.1% |
| Public | 23.1% | 22.7% | 22.3% | 22.4% | 22.2% | 15.2% | 15.2% | 15% | 15.2% | 14.9% | 15.1% | 15.9% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 100% | 100% | 100% | 100% | 94.6% |
| No. of Shareholders | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 88,658 | 80,910 | 75,284 | 81,877 | 85,230 | 99,149 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Behryanda Limited | Shareholding of Promoter and Promoter Group | 33.3% | 12.75 Cr |
| Jusmirial Holdings Limited | Shareholding of Promoter and Promoter Group | 24.2% | 9.24 Cr |
| Dsp Regular Savings Fund | Public Shareholding | 4.3% | 1.64 Cr |
| Icic Preduential Health Care And Diaganostic | Public Shareholding | 4.2% | 1.60 Cr |
| Jasub Property Holdings Llp | Public Shareholding | 3.8% | 1.47 Cr |
| Sbi Mnc Fund | Public Shareholding | 3.3% | 1.27 Cr |
| Jasti Property And Equity Holdings Private Limited | Public Shareholding | 2.5% | 96,16,009 |
| Hdfc Trustee Company Limited - Hdfc Tax Saver Fund | Public Shareholding | 2.2% | 82,49,905 |
| Sbi Life Insurance Co. Ltd | Public Shareholding | 1.8% | 66,99,607 |
| Invesco India Contra Fund | Public Shareholding | 1.7% | 64,64,885 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Behryanda Limited | 12.75 Cr | 100% | 2026-06-30 |
| Jusmirial Holdings Limited | 8.04 Cr | 87.1% | 2026-06-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Vivek Sharma | Chairman & Exec. Director | 2025 |
| Vinod Padikkal | Non-Exec & Non-Independent Dir | 2025 |
| K G Ananthakrishnan | Independent Non Exe. Director | 2025 |
| Matangi Gowrishankar | Independent Non Exe. Director | 2025 |
| Vinod Rao | Independent Non Exe. Director | 2025 |
| U B Pravin Rao | Independent Non Exe. Director | 2025 |
| Jaishankar Krishnan | Independent Non Exe. Director | 2025 |
| Pankaj Patwari | Non Executive Director | 2025 |
| Shweta Jalan | Non Executive Director | 2025 |
| KUNDAN KUMAR JHA | CS / Compliance Officer / Legal Head | 2025 |
| Himanshu Agarwal | Whole Time Director & Chief Financial Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Manufacturing of Bulk Drugs & Inter | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| USA | ₹495 Cr | 24.7% |
| Europe | ₹712 Cr | 35.6% |
| India | ₹308 Cr | 15.4% |
| Rest of the world | ₹488 Cr | 24.4% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹1 | 3,534 | 38 | 38 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-05 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 2 | 0 | 0 | 25 | 0 | 27 |
| 2025 | 0 | 0 | 0 | 7 | 0 | 7 |
| 2025 | 0 | 0 | 0 | 18 | 0 | 18 |
Insider / Designated-Person Trades
1 recent disclosure(s)
Jusmiral Holdings LimitedDisposal · 3,41,48,000
Substantial Acquisitions (SAST)
6 disclosure(s)
Market07/08/2026 · 28,99,996
Inter-se Transfer23/02/2026 · 77,00,000
Inter-se Transfer18/02/2026 · 70,00,000
Market18/02/2026 · 78,76,948
Release Of Encumbrances18/09/2025 · —
Market18/09/2025 · 3,41,48,000
Company Information
🌐 www.suvenpharm.com ↗
📍 8-2-334 SDE Serene Chambers, 3 Floor Avenue 7 Road No 5, Hyderabad, Telangana, 500034
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search